What Is Psoriasis?
Psoriasis is an autoimmune disorder where rapid skin cell reproduction results in raised, red and scaly patches of skin. It is not contagious. It most commonly affects the skin on the elbows, knees, and scalp, though it can appear anywhere on the body.
Anyone can have psoriasis. About 7.5 million people in the U.S. are affected, and it occurs equally in men and women. Psoriasis can occur at any age but is most often diagnosed between the ages of 15 to 25. It is more frequent in Caucasians.
Psoriasis is a non-curable, chronic skin condition and there will be periods where the condition will improve, and other times it will worsen. The symptoms can range from mild, small, faint dry skin patches where a person may not suspect they have a skin condition to severe psoriasis where a person's entire body may be nearly covered with thick, red, scaly skin plaques.
The cause of psoriasis is unknown but a number of risk factors are suspected. There seems to be a genetic predisposition to inheriting the illness, as psoriasis is often found in family members. Environmental factors may play a part in conjunction with the immune system. The triggers for psoriasis what causes certain people to develop it remain unknown.
Psoriasis usually appears as red or pink plaques of raised, thick, scaly skin. However it can also appear as small flat bumps, or large thick plaques, ,. It most commonly affects the skin on the elbows, knees, and scalp, though it can appear anywhere on the body. The following slides will review some of the different types of psoriasis.
The most common form of psoriasis that affects about 80% of all sufferers is psoriasis vulgaris ("vulgaris" means common). It is also referred to as plaque psoriasis because of the well-defined areas of raised red skin that characterize this form. These raised red plaques have a flaky, silver-white buildup on top called scale, made up of dead skin cells. The scale loosens and sheds frequently.
Psoriasis that has small, salmon-pink colored drops on the skin is guttate psoriasis, affecting about 10% of people with psoriasis. There is usually a fine silver-white buildup (scale) on the drop-like lesion that is finer than the scale in plaque psoriasis. This type of psoriasis if commonly triggered by a streptococcal (bacterial) infection. About two to three weeks following a bout of strep throat, a person's lesions may erupt. This outbreak can go away and may never recur.
Inverse psoriasis (also called intertriginous psoriasis) appears as very red lesions in body skin folds, most commonly under the breasts, in the armpits, near the genitals, under the buttocks, or in abdominal folds. Sweat and skin rubbing together irritate these inflamed areas.
Pustular psoriasis consists of well-defined, white pustules on the skin. These are filled with pus that is non-infectious. The skin around the bumps is reddish and large portions of the skin may redden as well. It can follow a cycle of redness of the skin, followed by pustules and scaling.
Erythrodermic psoriasis is a rare type of psoriasis that is extremely inflammatory and can affect most of the body's surface causing the skin to become bright red. It appears as a red, peeling rash that often itches or burns.
Psoriasis commonly occurs on the scalp, which may cause fine, scaly skin or heavily crusted plaque areas. This plaque may flake or peel off in clumps. Scalp psoriasis may resemble seborrheic dermatitis, but in that condition the scales are greasy.
Psoriatic arthritis is a type of arthritis (inflammation of the joints) accompanied by inflammation of the skin (psoriasis). Psoriatic arthritis is an autoimmune disorder where the body's defenses attack the joints of the body causing inflammation and pain. Psoriatic arthritis usually develops about 5 to 12 years after psoriasis begins and about 5-10% of people with psoriasis will develop psoriatic arthritis.
In some cases, psoriasis may involve only the fingernails and toenails, though more commonly nail symptoms will accompany psoriasis and arthritis symptoms. The appearance of the nails may be altered and affected nails may have small pinpoint pits or large yellow-colored separations on the nail plate called "oil spots." Nail psoriasis can be hard to treat but may respond to medications taken for psoriasis or psoriatic arthritis. Treatments include topical steroids applied to the cuticle, steroid injections at the cuticle, or oral medications.
Right now there is no cure for psoriasis. The disease can go into remission where there are no symptoms or signs present. Current research is underway for better treatments and a possible cure.
Psoriasis is not contagious even with skin-to-skin contact. You cannot catch it from touching someone who has it, nor can you pass it on to anyone else if you have it.
Psoriasis can be passed on from parents to children, as there is a genetic component to the disease. Psoriasis tends to run in families and often this family history is helpful in making a diagnosis.
There are several types of doctors who may treat psoriasis. Dermatologists specialize in the diagnosis and treatment of psoriasis. Rheumatologists specialize in the treatment of joint disorders, including psoriatic arthritis. Family physicians, internal medicine physicians, rheumatologists, dermatologists, and other medical doctors may all be involved in the care and treatment of patients with psoriasis.
There are some home remedies that may help minimize outbreaks or reduce symptoms of psoriasis:
The first line of treatment for psoriasis includes topical medications applied to the skin. The main topical treatments are corticosteroids (cortisone creams, gels, liquids, sprays, or ointments), vitamin D-3 derivatives, coal tar, anthralin, or retinoids. These drugs may lose potency over time so often they are rotated or combined. Ask you doctor before combining medications, as some drugs should not be combined.
Ultraviolet (UV) light from the sun slows the production of skin cells and reduces inflammation and can help reduce psoriasis symptoms in some people and artificial light therapy may be used for other people. Sunlamps and tanning booths are not proper substitutes for medical light sources. There are two main forms of light therapy:
If topical treatment and phototherapy have been tried and have failed, medical treatment for psoriasis includes systemic drugs taken either orally or by injection. Drugs including methotrexate, adalimumab (Humira), ustekinumab (Stelara), secukinumab (Cosentyx), ixekizumab (Taltz), and infliximab (Remicade) block inflammation to help slow skin cell growth. Systemic drugs may be recommended for people with psoriasis that is disabling in any physical, psychological, social, or economic way.
The prognosis for patients with psoriasis is good. Though the condition is chronic and is not curable, it can be controlled effectively in many cases. Studies for future treatments look promising and research to find ways to battle psoriasis is ongoing.
IMAGES PROVIDED BY:
REFERENCES:
2005-2016 WebMD, LLC. All rights reserved.
See the rest here:
Types of Psoriasis: Medical Pictures and Treatments
- Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment ... - Dermatology Times - April 18th, 2024 [April 18th, 2024]
- Psoriasis Patients with Arthralgia At Increased Risk of Psoriatic Arthritis Development - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Diagnosing Psoriatic Arthritis for the Dermatologist: Guidance From the Experts - Medscape - April 18th, 2024 [April 18th, 2024]
- Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg - MD Magazine - April 18th, 2024 [April 18th, 2024]
- The Impact of Pediatric Plaque Psoriasis on Children and Caregivers - HMP Global Learning Network - April 18th, 2024 [April 18th, 2024]
- Guselkumab Led to Improvements Over Several Psoriatic Arthritis Disease Domains - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Dual Diagnosing and Managing Psoriasis and Psoriatic Arthritis - The Dermatologist - April 18th, 2024 [April 18th, 2024]
- Etanercept Effective for Psoriasis, Rheumatic Disease Among Patients Extending Treatment After 12-Weeks - MD Magazine - February 9th, 2024 [February 9th, 2024]
- High Response Rates in Psoriasis With Oral IL-23 Inhibitor - Medpage Today - February 9th, 2024 [February 9th, 2024]
- Psoriasis and eczema have complex causes and consequences that researchers are seeking to uncover - Medical Xpress - February 9th, 2024 [February 9th, 2024]
- New Hope in Treatment of Plaque Psoriasis: Study Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- No Difference in Psoriasis Immune Response Despite Switch Between AVT02, Adalimumab - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Breakthrough in Psoriasis Treatment: JNJ-77242113 Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from Phase II Trial of Oral Interleukin Inhibitor for Psoriasis Treatment - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from the FRONTIER 1 Trial - An Exploration of JNJ-77242113 in the Treatment of Moderate-to ... - Medriva - February 9th, 2024 [February 9th, 2024]
- Personal Experience with Psoriatic Arthritis and Atopic Dermatitis - Medriva - February 9th, 2024 [February 9th, 2024]
- Rising Cost of Stelara: Impact on Patients and Johnson & Johnson's Market Performance - Medriva - February 9th, 2024 [February 9th, 2024]
- Global Psoriatic Arthritis (PsA) Treatment Market to achieve a remarkable US$ 15.6 Billion by 2028, - PharmiWeb.com - February 9th, 2024 [February 9th, 2024]
- Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter - May 31st, 2023 [May 31st, 2023]
- Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Janssen Announces Positive Results From Guselkumab Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Early Intervention with Secukinumab May Be Effective for Patients ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Scratching the itch, Lynk Pharmaceuticals trialling ointment for ... - OutSourcing-Pharma.com - May 31st, 2023 [May 31st, 2023]
- Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- For Patients With Birthmarks, Psychosocial Interventions Improved ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Nalbuphine ER Tablets Show Promise as Cough Therapy in ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- selectION reports results from SAD stage of si-544 Phase Ib trial - Clinical Trials Arena - May 31st, 2023 [May 31st, 2023]
- No Link Observed Between Gastrointestinal Tract Surgery and New ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Lynk doses first cohort in Phase Ib trial of psoriasis therapy - Clinical Trials Arena - May 30th, 2023 [May 30th, 2023]
- Metabolic Inflammation Contributes to Depression in Psoriatic Disease - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Encouraging Diversity and Inclusion for Patients With Psoriatic ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- The Weekly Roundup: May 22-26 - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Pediatric Psoriasis Market: A Study of the Industry's Key Applications ... - The Navajo Post - May 30th, 2023 [May 30th, 2023]
- Phototherapy Lamps Market are set to witness a CAGR of 5.8 ... - Digital Journal - May 30th, 2023 [May 30th, 2023]
- Celltrion seeks approval for Stelara biosimilar in EU - The Investor - May 30th, 2023 [May 30th, 2023]
- Peter Marinkovich, MD: FDA Approval of B-VEC Gene Therapy for ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Nick Stucky, MD, Phd: Implications for Media Influence on Minoxidil ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Tildrakizumab Linked With HRQOL Improvement in Psoriasis in a Real-World Setting - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Clinical Utility of Deucravacitinib for the Management of Moderate to ... - Dove Medical Press - May 18th, 2023 [May 18th, 2023]
- Covid-19 and Psoriasis: Is there a link? - Dunya News - May 18th, 2023 [May 18th, 2023]
- Improvement Needed in Study Interventions to Better Skin Self ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Adam Friedman, MD: Addressing Disparities in Care for Patients ... - MD Magazine - May 18th, 2023 [May 18th, 2023]
- Early-Infancy Meningitis Infection Linked With Increased Risk of ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- NOVN: Counting Down to PDUFA - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- Psoriatic Arthritis (PsA) Treatment Market is likely to register CAGR ... - Future Market Insights - May 18th, 2023 [May 18th, 2023]
- New campaign raises awareness of topical steroid withdrawal - Professional Beauty - May 18th, 2023 [May 18th, 2023]
- MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in... - February 2nd, 2023 [February 2nd, 2023]
- EVELO BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events (form 8-K) -... - February 2nd, 2023 [February 2nd, 2023]
- 12 Ways to Treat Psoriasis at Home - Healthline - January 22nd, 2023 [January 22nd, 2023]
- DTC Advertising Of Prescription Drugs In The U.S. Often Promotes Products With Comparatively Low Therapeutic Value - Forbes - January 19th, 2023 [January 19th, 2023]
- Types of Psoriasis: Pictures, Symptoms and Treatments - Healthline - December 18th, 2022 [December 18th, 2022]
- Psoriasis Pathogenesis and Treatment - PMC - PubMed Central (PMC) - November 23rd, 2022 [November 23rd, 2022]
- Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? - November 23rd, 2022 [November 23rd, 2022]
- Im a Dermatologist and These 7 Things Could Be Making Your Psoriasis Worse - Well+Good - October 19th, 2022 [October 19th, 2022]
- 'Worst time of the year for me to be covered in scabs': Amber Heard's Alleged Ex Cara Delevingne Revealed Her Psoriasis Struggle Made Kate Moss Scream... - October 19th, 2022 [October 19th, 2022]
- Psoriasis: What It Is, Symptoms, Causes, Types & Treatment - October 17th, 2022 [October 17th, 2022]
- What is psoriasis and which foods ease symptoms? - Evening Standard - October 17th, 2022 [October 17th, 2022]
- Chronic inflammatory diseases: what they are - Emergency Live International - October 17th, 2022 [October 17th, 2022]
- How remote care can deliver a step change in treatment for inflammatory skin conditions - PoliticsHome - October 17th, 2022 [October 17th, 2022]
- Probiotics Supplementation may Improve Symptoms of Hyperuricemia and Gout - Rheumatology Network - October 15th, 2022 [October 15th, 2022]
- Psoriasis Pathogenesis and Treatment - PubMed - October 2nd, 2022 [October 2nd, 2022]
- Best and Worst Drinks for Psoriasis - Everyday Health - October 2nd, 2022 [October 2nd, 2022]
- These Are the 10 Most Common Chronic Skin Conditionsand the Most Important Facts to Know About Them - Parade Magazine - October 2nd, 2022 [October 2nd, 2022]
- Survey Addresses Concerns Regarding Reproductive Healthcare Communication in Women with RA, PsA - Rheumatology Network - October 2nd, 2022 [October 2nd, 2022]
- Psoriasis Types, Symptoms & Causes | NIAMS - September 29th, 2022 [September 29th, 2022]
- What Is Psoriasis And Can It Be Treated? - Forbes - September 29th, 2022 [September 29th, 2022]
- Plaque Psoriasis Treated With Tildrakizumab Shown to be Effective in Real-World Settings - MD Magazine - September 29th, 2022 [September 29th, 2022]
- Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis - Business Wire - September 29th, 2022 [September 29th, 2022]
- 15 Items That Will Make Your Life With Psoriatic Arthritis Easier - BlackDoctor.Org - September 29th, 2022 [September 29th, 2022]
- Types of Psoriasis and Their Effects on the Immune System - Cureus - September 27th, 2022 [September 27th, 2022]
- MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis - BioSpace - September 27th, 2022 [September 27th, 2022]
- How diversity and inclusion continues to be incorporated in dermatology - PMLiVE - September 27th, 2022 [September 27th, 2022]
- Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp A - Benzinga - September 27th, 2022 [September 27th, 2022]
- Psoriasis Treatment Market Size to Hit USD 51.24 Bn by 2030 - GlobeNewswire - August 15th, 2022 [August 15th, 2022]
- Ventyx Sees Initiation Of Mid-Stage Psoriasis Study In Q4 2022 Following Positive Data From Initial-Stage - Benzinga - August 15th, 2022 [August 15th, 2022]